Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX4204 in Mild to Moderate Plaque Psoriasis
NCT06723171Phase 2Suspended
- Sponsor
- Io Therapeutics, Inc.
- Start
- Mar 2026
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing IRX4204 Arm with Placebo Arm (2 arms). Primary endpoint: Investigator Global Assessment at Day 42. Started Mar 2026; status: suspended.
02
Drugs
irx4204
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06723171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723171.